Trial Profile
An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GSK
- 25 Jul 2013 Results published in the Journal of Clinical Pharmacology.
- 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 04 Apr 2012 Actual patient number 24 added as reported by ClinicalTrials.gov.